A | ||||||||
---|---|---|---|---|---|---|---|---|
Variable | Trained Men Ambrotose AO® Pre | Trained Men Ambrotose AO® Post | Trained Men Placebo Pre | Trained Men Placebo Post | Untrained Men Ambrotose AO® Pre | Untrained Men Ambrotose AO® Post | Untrained Men Placebo Pre | Untrained Men Placebo Post |
WBC (103 μL)† | 4.5 ± 0.1 | 4.5 ± 0.2 | 5.1 ± 0.6 | 4.9 ± 0.3 | 5.7 ± 0.5 | 6.0 ± 0.4 | 5.9 ± 0.5 | 5.6 ± 0.5 |
RBC (106 μL)* | 4.9 ± 0.1 | 4.7 ± 0.1 | 4.9 ± 0.1 | 4.8 ± 0.1 | 4.7 ± 0.2 | 4.6 ± 0.2 | 4.6 ± 0.3 | 4.6 ± 0.2 |
Hemoglobin (g·dL-1)* | 14.7 ± 0.3 | 13.3 ± 0.5 | 14.8 ± 0.4 | 14.6 ± 0.3 | 14.8 ± 0.5 | 14.6 ± 0.5 | 14.6 ± 0.6 | 14.4 ± 0.4 |
Hematocrit (%)†* | 43.3 ± 0.8 | 41.8 ± 1.1 | 43.5 ± 1.0 | 42.3 ± 0.5 | 43.0 ± 1.0 | 41.9 ± 1.2 | 42.2 ± 2.0 | 41.2 ± 1.3 |
MCV (fL)** | 88.7 ± 2.2 | 89.0 ± 2.5 | 88.3 ± 2.3 | 88.3 ± 2.2 | 91.2 ± 2.6 | 90.8 ± 2.3 | 91.6 ± 2.2 | 91.0 ± 2.5 |
MCH (pg)** | 30.2 ± 1.0 | 30.5 ± 1.0 | 29.9 ± 1.0 | 30.3 ± 0.9 | 31.4 ± 1.0 | 31.7 ± 1.0 | 31.7 ± 1.0 | 31.9 ± 1.1 |
MCHC (g·dL-1)** | 34.0 ± 0.4 | 34.2 ± 0.2 | 33.9 ± 0.4 | 34.4 ± 0.4 | 34.5 ± 0.4 | 34.9 ± 0.3 | 34.5 ± 0.3 | 35.0 ± 0.4 |
RDW (%)** | 13.8 ± 0.4 | 13.2 ± 0.3 | 13.6 ± 0.3 | 13.5 ± 0.3 | 13.0 ± 0.2 | 13.1 ± 0.2 | 12.9 ± 0.2 | 12.9 ± 0.2 |
Platelets (103 μL)* | 208.0 ± 16.7 | 204.0 ± 13.9 | 214.4 ± 16.1 | 211.4 ± 21.7 | 217.6 ± 20.4 | 203.2 ± 21.0 | 208.0 ± 24.5 | 209.6 ± 24.3 |
Neutrophils (%) | 51.1 ± 4.5 | 50.0 ± 3.4 | 52.7 ± 4.9 | 51.0 ± 4.6 | 54.2 ± 2.6 | 58.0 ± 4.6 | 52.8 ± 2.1 | 53.6 ± 3.6 |
Lymphocytes (%) | 36.0 ± 3.8 | 37.4 ± 3.2 | 36.0 ± 4.4 | 36.4 ± 4.3 | 32.6 ± 2.1 | 30.2 ± 4.1 | 34.2 ± 1.3 | 33.5 ± 2.9 |
Monocytes (%)† | 7.7 ± 0.6 | 8.6 ± 0.8 | 7.6 ± 0.6 | 8.3 ± 0.5 | 7.4 ± 0.9 | 7.2 ± 1.2 | 7.0 ± 0.5 | 7.1 ± 0.9 |
Eosinophils (%)* | 4.9 ± 1.8 | 3.7 ± 0.8 | 3.1 ± 0.7 | 3.9 ± 0.6 | 5.2 ± 1.6 | 4.0 ± 1.0 | 5.8 ± 1.8 | 5.3 ± 1.8 |
Basophils (%) | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.6 ± 0.2 | 0.4 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.2 ± 0.2 | 0.5 ± 0.2 |
B | ||||||||
Variable | Trained Women Ambrotose AO ® Pre | Trained Women Ambrotose AO ® Post | Trained Women Placebo Pre | Trained Women Placebo Post | Untrained Women Ambrotose AO ® Pre | Untrained Women Ambrotose AO ® Post | Untrained Women Placebo Pre | Untrained Women Placebo Post |
WBC (103 μL)† | 5.1 ± 1.0 | 5.2 ± 0.7 | 4.7 ± 0.4 | 5.3 ± 0.7 | 5.6 ± 0.5 | 4.9 ± 0.3 | 5.0 ± 0.4 | 6.0 ± 0.8 |
RBC (106 μL)* | 4.2 ± 0.1 | 4.1 ± 0.1 | 4.2 ± 0.1 | 4.2 ± 0.1 | 4.2 ± 0.1 | 4.1 ± 0.1 | 4.2 ± 0.1 | 4.2 ± 0.2 |
Hemoglobin (g·dL-1)* | 13.4 ± 0.4 | 12.8 ± 0.3 | 13.2 ± 0.1 | 13.2 ± 0.2 | 12.5 ± 0.3 | 12.1 ± 0.4 | 12.3 ± 0.5 | 12.4 ± 0.6 |
Hematocrit (%)†* | 38.8 ± 1.0 | 37.1 ± 0.9 | 38.6 ± 0.4 | 37.9 ± 0.6 | 36.9 ± 0.8 | 35.0 ± 0.8 | 36.6 ± 1.4 | 36.5 ± 1.5 |
MCV (fL)** | 91.9 ± 1.7 | 91.4 ± 1.8 | 91.4 ± 2.0 | 90.8 ± 2.0 | 87.1 ± 1.2 | 85.8 ± 0.7 | 86.5 ± 0.9 | 86.2 ± 0.9 |
MCH (pg)** | 31.7 ± 0.7 | 31.6 ± 0.7 | 31.1 ± 0.7 | 31.5 ± 0.7 | 29.6 ± 0.4 | 29.7 ± 0.4 | 29.0 ± 0.4 | 29.3 ± 0.6 |
MCHC (g·dL-1)** | 34.6 ± 0.2 | 34.6 ± 0.2 | 34.1 ± 0.2 | 34.7 ± 0.2 | 33.9 ± 0.2 | 34.6 ± 0.3 | 33.6 ± 0.2 | 33.9 ± 0.4 |
RDW (%)** | 13.1 ± 0.3 | 13.3 ± 0.3 | 13.2 ± 0.2 | 13.5 ± 0.3 | 13.3 ± 0.5 | 13.6 ± 0.6 | 13.7 ± 0.6 | 13.7 ± 0.6 |
Platelets (103 μL)* | 234.3 ± 20.0 | 229.1 ± 17.1 | 246.1 ± 23.6 | 236.1 ± 18.8 | 256.9 ± 29.9 | 259.2 ± 25.4 | 254.8 ± 35.6 | 267.0 ± 34.2 |
Neutrophils (%) | 54.1 ± 5.5 | 56.3 ± 4.8 | 57.7 ± 4.7 | 58.8 ± 3.9 | 57.3 ± 3.5 | 56.0 ± 2.0 | 53.8 ± 3.2 | 58.3 ± 3.4 |
Lymphocytes (%) | 34.3 ± 4.9 | 31.0 ± 4.0 | 30.6 ± 4.4 | 29.3 ± 3.2 | 34.3 ± 3.5 | 35.8 ± 1.8 | 36.5 ± 2.6 | 32.5 ± 3.0 |
Monocytes (%)† | 8.0 ± 0.9 | 9.0 ± 1.0 | 7.3 ± 0.4 | 8.4 ± 0.6 | 6.1 ± 0.5 | 6.0 ± 0.5 | 6.2 ± 0.7 | 5.5 ± 0.8 |
Eosinophils (%)* | 3.0 ± 0.5 | 3.3 ± 0.9 | 3.4 ± 0.6 | 3.0 ± 0.6 | 1.7 ± 0.5 | 1.8 ± 0.2 | 3.0 ± 0.6 | 2.7 ± 0.5 |
Basophils (%) | 0.6 ± 0.2 | 0.4 ± 0.2 | 1.0 ± 0.0 | 0.5 ± 0.2 | 0.6 ± 0.2 | 0.3 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.2 |